Menu
Not yet recruiting NCT06948331

RADA16 for Aquablation Day Case

Phase II Interventional Hematuria Benign Prostatic Hyperplasia Lower Urinary Tract Symptoms

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: PuraStat.
Who it may be relevant to
Registry conditions: Hematuria, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms. Basic parameters: No limits · Male.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Pilot Proof of Concept Single-arm Study Using PuraStat Following the Aquablation Procedure to Assess Reduction of Hematuria to Allow for Same Day Discharge

Overview

This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge. The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation. The secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).

Interventions

  • Device PuraStat
    Sterile gel composed of synthetic peptide and sterile water; provided as a prefilled syringe. The will be applied to the inside of the prostate to help stop bleeding following Aquablation.

Primary outcome measures

  • Percentage of Patients Discharged the Same Day as Aquablation [Time frame: Day 1 (Operative Visit)]
Secondary outcome measures (2)
  • Mean Post-Operation Hematuria Grade [Time frame: Day 1 (Up to Hour 3 Post-Op)]
  • Percentage of Patients who Experience Dysuria during Follow-Up [Time frame: Up to Week 4 Post-Operation]

Eligibility criteria

Inclusion criteria

  • Any man undergoing Aquablation for LUTS due to BPH

Exclusion criteria

  • Unwilling to sign consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • NYU Langone Health — New York

Identifiers

NCT: NCT06948331 · 25-00109

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗